Results 231 to 239 of about 101,527 (239)
Some of the next articles are maybe not open access.
Selective Cyclooxygenase-2 Inhibitors
2004Publisher Summary Cyclooxygenase (prostaglandin G/H synthase) catalyzes the conversion of arachidonic acid (AA) into prostaglandin H2 as the first committed step of prostaglandin biosynthesis. This enzyme is known to be the target of acetyl salicylic acid (ASA) and non-steroidal anti-inflammatory drugs (NSAIDs).
openaire +2 more sources
Cyclooxygenase-2–specific inhibitors: are they safe?
The American Journal of Medicine, 2001The basic tenet of the cyclooxygenase-2 (COX-2) hypothesis rests on the fact that sparing of inhibition of COX-1 should result in greater safety than if both COX isoforms are inhibited. This increase in safety should be most evident in those organs and tissues in which COX-1 alone has important, necessary physiologic functions (e.g., the stomach and ...
openaire +3 more sources
Gastroduodenal Safety of Cyclooxygenase-2 Inhibitors
Current Pharmaceutical Design, 2003Cyclooxygenase-1 (COX-1) derived eicosanoids promote gastroprotective mucosal defenses and induce platelet aggregation. By sparing COX-1, COX-2 specific inhibitors provide effective anti-inflammatory and analgesic activity while substantially reducing the risk of peptic ulcer disease and GI bleeding compared to dual COX inhibitors (traditional NSAIDs).
openaire +3 more sources
Correction: Cyclooxygenase-2 Inhibitors
Annals of Pharmacotherapy, 1999Barbara Storyk Klostermeyer +1 more
openaire +2 more sources
Cyclooxygenase Inhibitors and Cardiovascular Risk
JAMA, 2007Frank Andersohn +2 more
openaire +2 more sources
Cyclooxygenase and lipoxygenase inhibitors in cancer therapy
Prostaglandins, Leukotrienes and Essential Fatty Acids, 1996G. Ara, B.A. Teicher
openaire +3 more sources
Aspirin and cyclooxygenase-2 inhibitors
American Journal of Health-System Pharmacy, 2003openaire +2 more sources